 Shares of Affimed AFMD, -6.14 were up 12.6 in premarket trading on Monday, the day after the company shared promising data about an experimental cancer therapy that uses cord blood cells. The new data cut showed deepening of complete responses and early signs of durability that we believe are validating for the program and overall approach, SVB Leerink analyst Daina Graybosch told investors on Monday morning. 